Is Health Politics Different?

被引:63
作者
Carpenter, Daniel [1 ]
机构
[1] Harvard Univ, Dept Govt, Cambridge, MA 02138 USA
来源
ANNUAL REVIEW OF POLITICAL SCIENCE, VOL 15 | 2012年 / 15卷
关键词
social policy; inequality; licensure; moral politics; illness and identity politics; approval regulation; INSURANCE; CARE; AMERICA; STATES;
D O I
10.1146/annurev-polisci-050409-113009
中图分类号
D0 [政治学、政治理论];
学科分类号
0302 ; 030201 ;
摘要
The aging of the global population, combined with changes in technology and cultural understandings of disease and the body, have thrust discussion and contestation over health into the center of local, national, and global politics. Is the politics of health different from the politics of other policy domains? On a number of dimensions, I conclude that it is. Voters and politicians in the developed world appear more likely to accept redistributive claims with respect to health than they are in other policy areas. Nations vary less widely in spending on health than on other functions of government and policy. Moral claims made about health are more likely to attach to its politics than are moral claims about the environment, labor, finance, and energy. More than these other realms, health politics encompasses issues regarding identity, the human body, and other personal matters that endow the health arena with greater significance. Bureaucratic agencies of state are more involved in the provision and regulation of health politics than in other areas, and the science-related nature of state expertise allows medical science itself to be sculpted in deeply political and administrative ways. The article concludes with reasons why political scientists should approach cross-policy generalizations cautiously, and with a call for greater engagement with health politics-to do for political science what health economics, the history of medicine, and medical sociology have done for other social science disciplines.
引用
收藏
页码:287 / 311
页数:25
相关论文
共 71 条
[11]   Regulatory errors with endogenous agendas [J].
Carpenter, Daniel ;
Ting, Michael M. .
AMERICAN JOURNAL OF POLITICAL SCIENCE, 2007, 51 (04) :835-852
[12]   Protection without capture: Product approval by a politically responsive, learning regulator [J].
Carpenter, DP .
AMERICAN POLITICAL SCIENCE REVIEW, 2004, 98 (04) :613-631
[13]   Groups, the media, agency waiting costs, and FDA drug approval [J].
Carpenter, DP .
AMERICAN JOURNAL OF POLITICAL SCIENCE, 2002, 46 (03) :490-505
[14]   The American Medical Association, Health Insurance Association of America, and Creation of the Corporate Health Care System [J].
Chapin, Christy Ford .
STUDIES IN AMERICAN POLITICAL DEVELOPMENT, 2010, 24 (02) :143-167
[15]  
Cohen A.B., 2004, Technology in American Health Care
[16]   EPIDEMICS AND AGENDAS - THE POLITICS OF NIGHTLY NEWS COVERAGE OF AIDS [J].
COLBY, DC ;
COOK, TE .
JOURNAL OF HEALTH POLITICS POLICY AND LAW, 1991, 16 (02) :215-249
[17]  
Daemmrich ArthurA., 2004, Pharmacopolitics: Drug Regulation in the United States and Germany
[18]  
Daniels Norman, 2001, American Journal of Bioethics, V1, P2, DOI 10.1162/152651601300168834
[19]  
Derthick Martha., 2002, SMOKE LEGISLATION LI
[20]  
Dewan S, 2009, COMP PUBLIC SPENDING